Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
作者： John K. Marshall , James M. Pellissier , Cheryl L. Attard , Sheldon X. Kong , Michael A. Marentette
DOI: 10.2165/00019053-200119100-00005
关键词:
摘要: Background: Clinical trials have shown rofecoxib, a selective inhibitor of cyclo-oxygenase-2, to be associated with fewer gastrointestinal complications than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs).
springer.com
sci-hub.se 参考文章(34)
Mark A. Korsten, Richard Jaszewski, Richard H. White, John G. Fort, Timothy T. Schubert, Jeffrey B. Raskin, Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. The American Journal of Gastroenterology. ,vol. 91, pp. 223- 227 ,(1996)
Judith D. Bentkover, Andrew M. Baker, Herbert Kaplan, Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. PharmacoEconomics. ,vol. 5, pp. 335- 342 ,(1994) , 10.2165/00019053-199405040-00007
Ingela Wiklund, Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. Canadian Journal of Gastroenterology & Hepatology. ,vol. 13, pp. 129- 133 ,(1999) , 10.1155/1999/171408
R. Knill-Jones, M. Drummond, H. Kohli, L. Davies, Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgraduate Medical Journal. ,vol. 66, pp. 639- 646 ,(1990) , 10.1136/PGMJ.66.778.639
Fred E. Silverstein, Misoprostol Reduces Serious Gastrointestinal Complications in Patients with Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs Annals of Internal Medicine. ,vol. 123, pp. 241- 249 ,(1995) , 10.7326/0003-4819-123-4-199508150-00001
Thomas A. Burke, Richard A. Zabinski, Daniel Pettitt, Nikos Maniadakis, Clement J. Maurath, Jay L. Goldstein, A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. PharmacoEconomics. ,vol. 19, pp. 33- 47 ,(2001) , 10.2165/00019053-200119001-00003
Sherine E. Gabriel, R. Liisa Jaakkimainen, Claire Bombardier, The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis & Rheumatism. ,vol. 36, pp. 447- 459 ,(1993) , 10.1002/ART.1780360404
Grant W. Cannon, Jacques R. Caldwell, Peter Holt, Barry McLean, Beth Seidenberg, James Bolognese, Elliot Ehrich, Suarabh Mukhopadhyay, Brian Daniels, Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one‐year, randomized, clinical trial in patients with osteoarthritis of the knee and hip Arthritis & Rheumatism. ,vol. 43, pp. 978- 987 ,(2000) , 10.1002/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0
Richard A. Zabinski, Thomas A. Burke, Jeffery Johnson, Fr??d??ric Lavoie, Catherine Fitzsimon, Roma Tretiak, Jeremy V.M. Chancellor, An Economic Model for Determining the Costs and Consequences of Using Various Treatment Alternatives for the Management of Arthritis in Canada PharmacoEconomics. ,vol. 19, pp. 49- 58 ,(2001) , 10.2165/00019053-200119001-00004
M.J.S. Langman, J. Weil, P. Wainwright, D.H. Lawson, M.D. Rawlins, R.F.A. Logan, M. Murphy, M.P. Vessey, D.G. Colin-Jones, Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs The Lancet. ,vol. 343, pp. 1075- 1078 ,(1994) , 10.1016/S0140-6736(94)90185-6